Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162032 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
A Phase 3 study, sponsored by Lantheus Medical Imaging.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT00162032 is a Phase 3 study that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 445 participants.
The verdict
NCT00162032, a Phase 3 study, has completed, sponsored by Lantheus Medical Imaging.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
Interventions
- DRUG Sestamibi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162032
The ClinicalTrials.gov registry entry for NCT00162032 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sestamibi is the first listed.
NCT00162032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162032 about?
NCT00162032 is a clinical study titled "A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease". Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
What is the current status of trial NCT00162032?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2005-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00162032?
The interventions under investigation include: Sestamibi (DRUG).
Who is sponsoring clinical trial NCT00162032?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.